Home › New Data from KEYNOTE-028, Mercks Trial Evaluating KEYTRUDA (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
 

Keywords :   


New Data from KEYNOTE-028, Mercks Trial Evaluating KEYTRUDA (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress

2015-09-27 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Findings Show Anti-Tumor Activity for KEYTRUDA in Two Gastrointestinal Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the companys anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data range types presented

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Tropical Storm Lane Graphics
02.11Subtropical Storm Patty Graphics
02.11Tropical Storm Lane Forecast Discussion Number 4
02.11Subtropical Storm Patty Wind Speed Probabilities Number 2
02.11Summary for Tropical Storm Lane (EP3/EP132024)
02.11Subtropical Storm Patty Public Advisory Number 2
02.11Subtropical Storm Patty Forecast Advisory Number 2
02.11Subtropical Storm Patty Update Statement
More »